Laura Rivino - Infectious Diseases

Author Information

Laura Rivino is a notable researcher in the field of Infectious Diseases, currently affiliated with the Emerging Infectious Diseases Programme at Duke-NUS Medical School in Singapore and the School of Cellular and Molecular Medicine at the University of Bristol in the UK. Her work is focused on understanding the immune responses and pathogenesis of various viral infections, including COVID-19, dengue, Zika, and hepatitis B.

Research Contributions

Laura Rivino has made significant contributions to the field of infectious diseases, with a particular focus on understanding immune responses in viral infections. Her research includes exploring the hyperactive immature state of neutrophils in severe COVID-19, the role of natural killer cell function and genetic polymorphisms in severe dengue, and immune cell phenotypes associated with dengue virus infection severity. Additionally, she has investigated the adaptive humoral and cellular immunity required to prevent Zika virus infection and the effects of hepatitis B surface antigen on T cells in chronic HBV infection. Her work aims to provide insights into potential therapeutic strategies and vaccine development for these infectious diseases.

Aliases

Laura Rivino is also known by other aliases including L Rivino and L. Rivino.

Publication and Citation Metrics

Metric	Value
Citation Count	3586
H-index	24
Paper Count	60

Publications:

Neutrophils in severe COVID-19 are characterized by a hyperactive immature state and maintained CXCR2 expression

DOI: 10.1101/2022.03.23.22272828

Year: 2022

Hyperinflammatory syndrome, natural killer cell function and genetic polymorphisms in the pathogenesis of severe dengue.

DOI: 10.1093/infdis/jiac093

Year: 2022

Immune cell phenotypes associated with disease severity and long-term neutralizing antibody titers after natural dengue virus infection

DOI: 10.1016/j.xcrm.2021.100278

Year: 2021

Young infants exhibit robust functional antibody responses and restrained IFN-γ production to SARS-CoV-2

DOI: 10.1016/j.xcrm.2021.100327

Year: 2021

Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?

DOI: 10.1016/S2666-5247(21)00087-2

Year: 2021

Association of Macrophage Activation Syndrome, Natural Killer (NK) Cell Function and Genetic Polymorphisms With Dengue Disease Severity

DOI: 10.2139/ssrn.3847777

Year: 2021

Live vaccine infection burden elicits adaptive humoral and cellular immunity required to prevent Zika virus infection

DOI: 10.1016/j.ebiom.2020.103028

Year: 2020

The association of obesity and severe dengue: possible pathophysiological mechanisms.

DOI: 10.1016/j.jinf.2020.04.039

Year: 2020

Dengue: Status of current and under‐development vaccines

DOI: 10.1002/rmv.2101

Year: 2020

Effects of Hepatitis B Surface Antigen on Virus-specific and Global T Cells in Patients With Chronic HBV infection.

DOI: 10.1053/j.gastro.2020.04.019

Year: 2020

What are the Key Factors in Resource Allocation?

How to Interpret Imaging Results?

Why is Mosquito Control Crucial?

How Does the FDA Ensure the Safety of Antiviral Drugs?

What should be done if a condom fails?

Are There Any Technological Advances in Hygiene Practices?

How Does the CDC Educate the Public About Infectious Diseases?

Which Infections Are Most Affected?

What is hygiene and why is it important?

What is the Global Impact of Dengue Hemorrhagic Fever?

Partnered Content Networks

Relevant Topics